<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692781</url>
  </required_header>
  <id_info>
    <org_study_id>CP-6-001</org_study_id>
    <nct_id>NCT02692781</nct_id>
  </id_info>
  <brief_title>A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects</brief_title>
  <official_title>A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opko Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Opko Biologics</source>
  <brief_summary>
    <textblock>
      MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active
      moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM
      and is an agonist for both glucagon-like peptide-1 (GLP1) and glucagon (GCG) receptors. The
      peptide is a natural appetite suppressant, secreted by L-cells in the digestive system
      following food intake leading to a decrease in gastric emptying, satiety after crossing the
      blood-brain barrier, and regulation of insulin and glucose levels. Thus, MOD-6031 is being
      developed as a treatment for high risk subjects (obese) to increase weight loss, reduce food
      intake and increase glycemic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a a randomized, single-blind, placebo-controlled, single-dose, dose-escalation
      study. Five escalating dose groups are planned, with 8 subjects per dose group, randomized in
      3:1 ratio to receive a single dose of MOD-6031 or matching Placebo (6 MOD-6031 to 2 placebo
      subjects). The initial MOD-6031 dose will be 20 mg, followed by single doses of 50 mg, 100
      mg, 150 mg and 200 mg. Each subject will receive a single study drug injection in the morning
      (dosing day designated as Day 0) and will be monitored for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 15, 2016</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(inf) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T(½) of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of MOD-6031 and its hydrolyzed derivatives (PEG-FMS and OXM peptide)</measure>
    <time_frame>0 to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg MOD-6031 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg MOD-6031 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg MOD-6031 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg MOD-6031 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg MOD-6031 / Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOD-6031</intervention_name>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_label>Dose Cohort 4</arm_group_label>
    <arm_group_label>Dose Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_label>Dose Cohort 4</arm_group_label>
    <arm_group_label>Dose Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, between 18 to 55 years of age.

          -  BMI 27-35 Kg/m2 (inclusive).

          -  Generally good health.

          -  Triglyceride ≤ 400mg/ml

          -  ECG with no clinically significant abnormalities.

          -  Negative HIV, hepatitis B or hepatitis C serology tests at screening

          -  No significant abnormalities in clinical laboratory parameters

          -  No history of alcohol or drug abuse.

        Exclusion Criteria:

          -  History of clinically significant medical condition.

          -  Any cardiac conduction defect.

          -  Any acute or unstable disease.

          -  History of malignancy diagnosed within the past 5 years.

          -  Known or suspected diabetes and/or HbA1C &gt;6.4% on screening.

          -  Known allergy to any drug.

          -  Treatment with weight loss drugs (within 3 months prior to dosing).

          -  Liposuction or other surgery for weight loss within the last year.

          -  Evidence of eating disorders (bulimia, binge eating).

          -  History of regular alcohol consumption exceeding.

          -  Use of tobacco or nicotine-containing products.

          -  Subjects that have difficulty fasting or consuming the standard meals that will be
             provided.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

